QPPV.COM KNOWLEDGE ASSESSMENT

Bezlotoxumab: Mechanism, EU Use and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Bezlotoxumab: Mechanism, EU Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information is most useful when documenting a suspected infusion-related reaction to bezlotoxumab?

Only the final diagnosis, without the event timeline. Onset relative to infusion, symptoms, observations, infusion rate, any interruption, treatment and outcome. Only the patient’s CDI test result. Only whether the patient had received antibiotics in the past.

Question 2 of 10 Which statement best describes the QPPV’s role in relation to the pharmacovigilance system described in the article?

The QPPV personally manages every patient receiving bezlotoxumab. The QPPV oversees the marketing authorisation holder’s pharmacovigilance system, while clinical teams remain responsible for patient management. The QPPV determines whether every individual recurrence is caused by bezlotoxumab. The QPPV replaces the need for traceable case-processing records.

Question 3 of 10 How should the heart-failure information in the EU product context be applied?

It establishes that bezlotoxumab causes heart failure in every treated patient. It identifies a label-based caution, particularly relevant to patients with a history of congestive heart failure. It demonstrates that heart failure is unrelated to bezlotoxumab in all patients. It means that any cardiac symptom after infusion must be coded as confirmed drug-induced heart failure.

Question 4 of 10 Which molecular target is consistent with the described mechanism of bezlotoxumab?

C. difficile toxin B C. difficile toxin A The C. difficile cell wall A host receptor responsible for restoring intestinal flora

Question 5 of 10 Which approach is most appropriate for aggregate safety review of bezlotoxumab cases?

Combine initial CDI, recurrence, persistent symptoms and adverse reactions into a single undifferentiated category. Distinguish infection outcomes from adverse reactions and consider relevant factors such as age, prior episodes, antibiotic regimen, infusion timing and CHF history where data permit. Exclude antibiotic exposure because it does not affect interpretation. Treat every report of diarrhoea as confirmed recurrence.

Question 6 of 10 Which distinction is important when reviewing a patient’s gastrointestinal course after the initial CDI episode?

Initial CDI, recurrence, persistent symptoms and adverse reactions should be distinguishable in the assessment. All diarrhoea after the first episode should be treated as recurrence. Persistent symptoms and recurrent infection are equivalent diagnoses. Any gastrointestinal symptom after infusion should be classified as hypersensitivity.

Question 7 of 10 A follow-up test is positive for C. difficile in a patient with new diarrhoea. What is the most appropriate interpretation for case assessment?

A positive test always establishes symptomatic recurrent CDI. A positive test should be interpreted alongside symptoms, clinical diagnosis and other available evidence. A positive test establishes that bezlotoxumab failed to neutralise toxin B. A positive test should be disregarded if the patient previously received an antibody.

Question 8 of 10 Which recordkeeping practice best supports inspection-ready pharmacovigilance evidence?

Retain only the final causality conclusion. Maintain traceable records showing product and antibiotic exposure, event definitions, missing information and how conclusions were reached. Keep only spontaneous-report totals because individual case details are unnecessary. Remove the original clinical information after coding is complete.

Question 9 of 10 Which statement correctly distinguishes seriousness, expectedness and individual causality in case processing?

They are interchangeable labels and should be determined together as one conclusion. They are separate assessments and should remain distinct under applicable EU procedures. A serious event is automatically unexpected and caused by the product. An expected event cannot be serious or related to treatment.

Question 10 of 10 When making a current EU regulatory or clinical assessment of Zinplava, which source approach is most appropriate?

Rely exclusively on the original authorisation-era information, regardless of later updates. Use the current EMA product information and product record, alongside applicable requirements and clinical judgement. Use spontaneous-report narratives instead of the product information. Treat the educational article as a substitute for the current Summary of Product Characteristics.

Bezlotoxumab: Mechanism, EU Use and Pharmacovigilance — Knowledge Assessment

Cookie Settings